Press release
Plaque Psoriasis Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Plaque Psoriasis Treatment Landscape. Click here to read more @ Plaque Psoriasis Pipeline Outlook [https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Plaque Psoriasis Pipeline Report
* On 02 September 2025, Bristol-Myers Squibb conducted a Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis
* DelveInsight's Plaque Psoriasis pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Plaque Psoriasis treatment.
* The leading Plaque Psoriasis Companies such as Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics and others.
* Promising Plaque Psoriasis Therapies such as EDP1815, AX-158, RWJ-445380, Tapinarof cream, 1%, Bimekizumab, TAK-279 and others.
Gain in-depth knowledge of key Plaque Psoriasis clinical trials, emerging drugs, and market opportunities @ Plaque Psoriasis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Plaque Psoriasis Emerging Drugs Profile
* ARQ-151: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase-4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases the production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the systemic treatment of plaque psoriasis and the topical treatment of atopic dermatitis. Topical roflumilast cream is a highly potent, selective PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is developing for chronic plaque psoriasis and atopic dermatitis.
* ABY-035: Affibody
ABY-035 is a novel bispecific agent, potently targeting both subunits of IL-17A as well as albumin. ABY-035 has been specifically designed to utilize the strengths of Affibody's technology platform to create a very small protein drug (18 kDa, an eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serum albumin.
* AK101: Akeso Biopharma
AK101 injection is a novel antibody drug developed independently by the Company under the National Major Innovative Drug Projects. It is intended to be used for the treatment of autoimmune diseases such as psoriasis, Crohn's disease, ulcerative colitis and lupus. AK101 clinically treats autoimmune diseases by blocking the biological activities of cytokines IL-12 and IL-23. Johnson & Johnson's Ustekinumab (trade name: Stelara) which has the same drug targets has been approved by the FDA for the treatment of psoriasis, Crohn's disease, and ulcerative colitis, and yielded US$6.4 billion in sales in 2019. Currently, it is in Phase III stage of clinical trial evaluation to treat Plaque Psoriasis
The Plaque Psoriasis pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Plaque Psoriasis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Plaque Psoriasis Treatment.
* Plaque Psoriasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Plaque Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Plaque Psoriasis market.
Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Plaque Psoriasis Unmet Needs [https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Plaque Psoriasis Companies
Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics and others.
Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Plaque Psoriasis Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
See the latest progress in drug development and clinical research @ Plaque Psoriasis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Plaque Psoriasis Pipeline Report
* Coverage- Global
* Plaque Psoriasis Companies:- Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutic s and others.
* Plaque Psoriasis Therapies- EDP1815, AX-158, RWJ-445380, Tapinarof cream, 1%, Bimekizumab, TAK-279 and others.
* Plaque Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Plaque Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Immunological and Autoimmune Disorders Research-Access the Full Plaque Psoriasis Pipeline Analysis Today! @ Plaque Psoriasis Drugs and Companies [https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Plaque Psoriasis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Plaque Psoriasis - DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* ARQ-151: Arcutis Biotherapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ABY-035: Affibody
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CT303: GC Cell
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Plaque Psoriasis Key Companies
* Plaque Psoriasis Key Products
* Plaque Psoriasis- Unmet Needs
* Plaque Psoriasis- Market Drivers and Barriers
* Plaque Psoriasis- Future Perspectives and Conclusion
* Plaque Psoriasis Analyst Views
* Plaque Psoriasis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=plaque-psoriasis-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/plaque-psoriasis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Plaque Psoriasis Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential here
News-ID: 4174542 • Views: …
More Releases from ABNewswire
Talent Hero Media Named #1 Marketing Agency for Recruiting Firms in North Americ …
Digital marketing expertise and recruiting industry specialization recognized for driving measurable lead generation and brand growth
Talent Hero Media has been named the #1 marketing agency for recruiting firms in North America by Business Growth Insider, following an extensive evaluation process that assessed client results, industry expertise, campaign performance, and specialization depth across leading agencies serving the recruitment sector.
The recognition from Business Growth Insider incorporated anonymous surveys of recruiting firm executives…
Dr. Otto Placik Addresses Growing Demand for Body Contouring in the Age of GLP-1 …
Image: https://www.abnewswire.com/upload/2025/09/c1d88e2afca5cba16a029593e9ed9fe8.jpg
With the arrival of advanced weight loss medications such as GLP-1 receptor agonists and the anticipated introduction of Retatrutide, which activates GIP and GCG receptors, the medical community is witnessing a new era of medical weight management. These therapies, once primarily reserved for individuals with diabetes or severe obesity, are now being used more broadly to help patients achieve transformative reductions in body weight.
The results are often dramatic, with…
Billionaire Learning Academy & Knowledge Centre Raises Over $23K at Annual Fundr …
Image: https://www.abnewswire.com/upload/2025/09/ea30c6de64c1c05b165c5241f3c067ee.jpg
Eustis, Florida - September 30, 2025 - The Billionaire Learning Academy & Knowledge Centre (BLAKC) proudly announces the success of its 4th Annual Bash and Fundraiser, held on August 3, 2025, at the Eustis Community Center, located at 601 Northshore Dr, Eustis, FL 32726. The event, themed "Back Billionaire Future," brought together supporters, local partners, and community advocates to celebrate empowerment, raise funds, and foster unity.
This year's event reached…
ETCETERA and Adam Shenk Dominate the Charts: New Single Holds #1 Spot on Top 40 …
New York, NY - September 30, 2025 - Award-Winning Hip Hop Artist, ETCETERA, has achieved a defining career milestone as his latest single featuring the soulful Adam Shenk secures the #1 position on the Top 40 Radio Charts for three consecutive weeks. The track, released September 20, 2025, appears both as a deluxe version and in its original form on his acclaimed third studio album, SAGITTARIUS (IDOL MUSIC GROUP INC.…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
